Hisamichi Naito

2.4k citations
45 papers · 1.7k indexed · h-index 20

Hisamichi Naito

45 papers receiving 1.7k citations

Peers

Hisamichi Naito
Comparison fields: 5 of 93
  • Cancer Research 336
  • Immunology 412
  • Molecular Biology 943
  • Cell Biology 212
  • Pharmacology 190
Replace Olga Stenina‐Adognravi with:
Olga Stenina‐Adognravi United States
Magdalena L. Bochenek Germany
Hiroyasu Kidoya Japan
Daisuke Ogawa Japan
Amaya García de Vinuesa Netherlands
Chad L. Barber United States
Catherine Monnot France
Daniel Nyqvist Sweden
Shaoqiong Chen China
Meena S. Kumar United States
Hisamichi Naito relative to Olga Stenina‐Adognravi United States Olga Stenina‐Adognravi's profile →
Citations per field
00.5×1.5×
Olga Stenina‐Adognravi · 1×
Citations per year

Countries citing papers authored by Hisamichi Naito

Since Specialization
Citations

This map shows the geographic impact of Hisamichi Naito's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hisamichi Naito with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hisamichi Naito more than expected).

Fields of papers citing papers by Hisamichi Naito

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hisamichi Naito. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hisamichi Naito. The network helps show where Hisamichi Naito may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Hisamichi Naito, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Hisamichi Naito Line = papers co-authored together Hisamichi Naito links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20247
2 20243
3 20238
4 20233
5 201923
6 201833
7 2018141
8 201740
9 20179
10 201667
11 201611
12 201630
13 201557
14 20138
15 20137
16 2013244
17 201290
18 201155
19 200728
20 199645

About Hisamichi Naito

Hisamichi Naito is a scholar working on Cancer Research, Immunology and Immunology and Allergy, having authored 45 papers that have together received 1.7k indexed citations. Recurring topics across this work include Angiogenesis and VEGF in Cancer (17 papers), Zebrafish Biomedical Research Applications (6 papers), Cancer, Hypoxia, and Metabolism (5 papers), Apelin-related biomedical research (5 papers), Congenital heart defects research (4 papers), MicroRNA in disease regulation (4 papers), Cancer Cells and Metastasis (4 papers) and Axon Guidance and Neuronal Signaling (3 papers). The work is most often cited by research in Cancer Research (336 citations), Immunology (412 citations) and Molecular Biology (943 citations). Hisamichi Naito has collaborated with scholars based in Japan, United States and Germany. Frequent co-authors include Nobuyuki Takakura, Hiroyasu Kidoya, Tomohiro Iba, Taku Wakabayashi, Fumitaka Muramatsu, Susumu Sakimoto, Kazuhiro Takara, Daishi Yamakawa, Shizuo Akira and Takashi Satoh. Their work appears in journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026